Model A

•HM is a 43 years old male patient , he was c/o constipation,

bloody stool, nausea and vomiting . He thought for medical
advise
•Ultrasound was done and it showed a mass in the right colon
with three FHL(focal hepatic lesions), then colonoscopy was
recommended for biopsy.
•The pathological report of the taken biopsy revealed stage III
of cancer.
• when consulting the surgeon he said that the patient was
inoperable
1. the consultant decided to start
FOLFOX+BEVACIZUMAB regimen ,the first cycle was
given on 3/2/2023, so the next cycle date would
be…………………………
A.13/2/2023
B.25/2/2023
C. 17/2/2023
D. 10/2/2023
2. if you know that weight :61 kg, Ht:157 cm, so the
dose of oxaliplatin, bevacizumab
are……………………mg. respectively.
A. 158.33, 405
B. 155.77, 503
C.138.55, 305
D.140,300
3. The main adverse effect of oxaliplatin
is……………………..
A. Nephrotoxicity
B. Peripheral neuropathy
C. Diarrhea
D. hypertension
 4……………………….considered as side effect of
bevacizumab.
A. Nephrotoxicity
B. Neurotoxicity
C. Hypotension
D. Hypertension
5.”Bevacizumab” considered as………………
A. alkylating agent
B. anti metabolite
C. anti EGFR
D. anti VEGF
Model B
• ZA is a 33 years old female patient , she was c/o abdominal pain,
disturbed bowel habit and weight loss . She thought for medical
advise
• Ultrasound was done and it showed a mass in the left side of the
colon ,then colonoscopy was recommended for biopsy.
• The pathological report of the taken biopsy revealed a locally
advanced stage III of cancer.
• the oncologist decided to give her 6 cycles of FOLFIRI protocol after
surgery.
1.If you know that her weight was 57 kg, ht:160cm, so
the dose of irinotecan and leucovorin would
be…………………….respectively.
A. 636, 286.2 mg
B. 286.2, 663 mg
C . 286.2, 636 mg
D . 366, 268.2 mg
2. If the first cycle was given on 28/2/2023, so the next
cycle date would be…………………………
A.14/3/2023
B.21/3/2023
C. 7/3/2023
D. 28/3/2023
3.The main adverse effect of irinotecan
is……………………..
A. Nephrotoxicity
B. Peripheral neuropathy
C. Diarrhea
D. hypertension
4. The deficiency of……………………enzyme is
related to the sever and un expected toxicity of 5-Fu.
A. Cytochrome- 3A
B. Di hydro folate reductase
C. Thymidylate synthetase
D. Di hydro pyrimidine reductase
5.”Panitumab” considered as………………
A. alkylating agent
B. anti metabolite
C. anti EGFR
D. anti VEGF